# Precigen, Inc.

**PGEN**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001356090

# None

**No letter**

5 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $155.5M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway, thin data<br>not computable: dilution |
| **Inputs computable** | 5 of 14 |
| **Graded from** | filings received through Mar 25, 2026<br>212 days before the rescan; latest periodic filing 10-Q received Aug 4, 2026 |
| **Last close** | $6.39<br>2026-10-22; market equity $2.3B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 25, 2026*

We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 4.1** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *prior invested-capital observation is 1096 days earlier* | | | | | | |
| Accruals ratio | (108.3%) | (6.6%) | | 4.1 | 812 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 58.5** | | | | | | |
| Twelve-month failure probability | 0.05% | 0.06% | | 31.7 | 247 | 2026-06-30 |
| Altman Z double-prime | (50.41) | (0.30) | | 88.6 | 757 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 3.09x | 2.96x | | 55.2 | 840 | 2025-12-31 |
| **Growth and financing, sleeve percentile 69.5** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *four consecutive annual observations are required* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Asset growth, three years | (10.4%) | 2.1% | | 69.5 | 705 | 2025-12-31 |
| Net share issuance, one year | not computable | 2.4% | | | | |
| *prior share count is 296 days earlier* | | | | | | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 1.7 months |
| Thin data | 5 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-10-22 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 110.6% | 8.0% | 90 |
| Distance from 52-week high | (25.4%) | (29.6%) | 56 |
| EBIT to enterprise value | (4.7%) | (1.5%) | 42 |
| Free cash flow yield | (3.9%) | (0.9%) | 43 |
| Book value to price | 0.02 | 0.27 | 14 |
| Sales to price | 0.00 | 0.30 | 4 |
| Composite equity issuance, five years | 55.4% | 20.5% | 67 |
| Relative strength against the sector, log excess return | 0.53 | (0.13) | 90 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $16.3M |
| Operating cash flow, four quarters | -$114.2M |
| Months of runway | 1.7 |
| Days since last periodic filing | 80 (10-Q received Aug 4, 2026) |
| Median daily dollar volume, 63 sessions | $33.3M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | operating income | us-gaap:OperatingIncomeLoss | -$110.5M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 2 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$250.6M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 3 | income tax | us-gaap:IncomeTaxExpenseBenefit | $3,000 | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 4 | total debt | us-gaap:LongTermDebt | $93.2M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 5 | book equity | us-gaap:StockholdersEquity | $20.9M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 6 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $30.2M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 7 | total debt | us-gaap:LongTermDebt | $43.2M | 2022-12-31 | 2023-03-06 | 10-K | 23-000004 |
| 8 | book equity | us-gaap:StockholdersEquity | $126.3M | 2022-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $4.9M | 2022-12-31 | 2024-03-19 | 10-K | 24-000007 |
| 10 | net income | us-gaap:NetIncomeLoss | -$250.6M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 11 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$87.8M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 12 | assets | us-gaap:Assets | $155.5M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 13 | assets | us-gaap:Assets | $145.3M | 2024-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 14 | current assets | us-gaap:AssetsCurrent | $115.2M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 15 | current liabilities | us-gaap:LiabilitiesCurrent | $37.3M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 16 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$2.3B | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 17 | liabilities | us-gaap:Liabilities | $134.6M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 18 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $3.2M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 19 | operating income | us-gaap:OperatingIncomeLoss | -$505.6M | 2018-12-31 | 2019-03-01 | 10-K | 19-000004 |
| 20 | interest expense | us-gaap:InterestExpense | $8.5M | 2018-12-31 | 2019-03-01 | 10-K | 19-000004 |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $9.7M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 22 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $26.9M | 2022-12-31 | 2023-03-06 | 10-K | 23-000004 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $14.3M | 2021-12-31 | 2023-03-06 | 10-K | 23-000004 |
| 24 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $32.0M | 2020-12-31 | 2023-03-06 | 10-K | 23-000004 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $2.0M | 2025-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$68.2M | 2024-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $8.6M | 2024-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$66.9M | 2023-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.5M | 2023-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$65.0M | 2022-12-31 | 2025-03-19 | 10-K | 25-000007 |
| 31 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $4.9M | 2022-12-31 | 2025-03-19 | 10-K | 25-000007 |
| 32 | current assets | us-gaap:AssetsCurrent | $102.4M | 2024-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 33 | current liabilities | us-gaap:LiabilitiesCurrent | $21.5M | 2024-12-31 | 2026-03-25 | 10-K | 26-000009 |
| 34 | assets | us-gaap:Assets | $151.0M | 2023-12-31 | 2025-03-19 | 10-K | 25-000007 |
| 35 | assets | us-gaap:Assets | $216.0M | 2022-12-31 | 2024-03-19 | 10-K | 24-000007 |
| 36 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 353,928,672 | 2026-02-15 | 2026-03-25 | 10-K | 26-000009 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 295,165,060 | 2025-04-25 | 2025-04-28 | 10-K/A | 25-000011 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.